JP2019532105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532105A5 JP2019532105A5 JP2019541893A JP2019541893A JP2019532105A5 JP 2019532105 A5 JP2019532105 A5 JP 2019532105A5 JP 2019541893 A JP2019541893 A JP 2019541893A JP 2019541893 A JP2019541893 A JP 2019541893A JP 2019532105 A5 JP2019532105 A5 JP 2019532105A5
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- dry eye
- severe dry
- surgery
- treating severe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012530 fluid Substances 0.000 claims 30
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 15
- 206010013774 Dry eye Diseases 0.000 claims 15
- 239000003755 preservative agent Substances 0.000 claims 15
- 238000001356 surgical procedure Methods 0.000 claims 12
- 230000002335 preservative effect Effects 0.000 claims 8
- 239000012867 bioactive agent Substances 0.000 claims 6
- 239000003599 detergent Substances 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 210000000170 cell membrane Anatomy 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
- 229920002413 Polyhexanide Polymers 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- 229940124447 delivery agent Drugs 0.000 claims 2
- 239000006196 drop Substances 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940009662 edetate Drugs 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 231100000040 eye damage Toxicity 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- -1 haptens Substances 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 125000005430 oxychloro group Chemical group 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229940010747 sodium hyaluronate Drugs 0.000 claims 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022122165A JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2024209810A JP2025029084A (ja) | 2016-10-14 | 2024-12-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408559P | 2016-10-14 | 2016-10-14 | |
| US62/408,559 | 2016-10-14 | ||
| US201762516911P | 2017-06-08 | 2017-06-08 | |
| US62/516,911 | 2017-06-08 | ||
| PCT/IB2017/001364 WO2018069763A1 (en) | 2016-10-14 | 2017-10-02 | Method for establishing, restoring, and preserving homeostasis of the ocular surface |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122165A Division JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2024209810A Division JP2025029084A (ja) | 2016-10-14 | 2024-12-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532105A JP2019532105A (ja) | 2019-11-07 |
| JP2019532105A5 true JP2019532105A5 (cg-RX-API-DMAC7.html) | 2020-11-12 |
Family
ID=60766004
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541893A Pending JP2019532105A (ja) | 2016-10-14 | 2017-10-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2022122165A Pending JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2024209810A Pending JP2025029084A (ja) | 2016-10-14 | 2024-12-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122165A Pending JP2022153583A (ja) | 2016-10-14 | 2022-07-29 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2024209810A Pending JP2025029084A (ja) | 2016-10-14 | 2024-12-02 | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190240251A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3525799B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2019532105A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190068575A (cg-RX-API-DMAC7.html) |
| ES (1) | ES2909998T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE058672T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3525799T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018069763A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE058672T2 (hu) | 2016-10-14 | 2022-09-28 | I Com Medical Gmbh | Eljárás a szemfelület homeosztázisának megállapítására, helyreállítására és megõrzésére |
| WO2019202017A1 (en) * | 2018-04-18 | 2019-10-24 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| EP3852725A4 (en) * | 2018-09-20 | 2022-08-03 | The Hong Kong University of Science and Technology | EYE DROP COMPOSITIONS |
| US12268706B2 (en) | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| CN116096355A (zh) * | 2020-06-12 | 2023-05-09 | I.Com医疗有限责任公司 | 用于治疗角膜神经损伤或损失的高分子量透明质酸 |
| CN115989021A (zh) * | 2020-06-21 | 2023-04-18 | I.Com医疗有限责任公司 | 用于治疗和预防高眼压症和青光眼的基于透明质酸的制剂 |
| JP2025524369A (ja) * | 2022-06-08 | 2025-07-30 | ザ スケペンス アイ リサーチ インスティテュート，インコーポレイテッド | ドライアイ疾患を処置するための方法 |
| EP4591860A1 (en) * | 2024-01-23 | 2025-07-30 | FB Vision S.p.A. | Ophthalmic pharmaceutical composition for the prevention and treatment of dry eye syndrome |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1263606A (en) * | 1985-05-29 | 1989-12-05 | Jeffrey P. Gilbard | Non-toxic opthalmic preparations |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| JP3050898B2 (ja) * | 1990-07-06 | 2000-06-12 | 千寿製薬株式会社 | 水性医薬製剤 |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| IT1277707B1 (it) * | 1995-12-22 | 1997-11-11 | Chemedica Sa | Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare |
| SE9700827D0 (sv) * | 1997-03-07 | 1997-03-07 | Pharmacia & Upjohn Ab | Ophthalmic composition |
| TR200302105T4 (tr) * | 2000-04-07 | 2004-02-23 | Laboratoire Medidom S. A. | Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları. |
| US6528464B1 (en) * | 2001-08-17 | 2003-03-04 | Bausch & Lomb Incorporated | Composition and method for inhibiting uptake of biguanide antimicrobials by hydrogels |
| JP3779200B2 (ja) * | 2001-11-28 | 2006-05-24 | 電気化学工業株式会社 | ヒアルロン酸及び／又はその塩の水溶液の安定化組成物 |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| CN103638040A (zh) * | 2002-07-03 | 2014-03-19 | 派瑞克科学公司 | 透明质酸组合物以及使用方法 |
| DE10360425A1 (de) | 2003-12-19 | 2005-07-28 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung |
| EP1942912B1 (en) * | 2005-10-12 | 2016-12-14 | Seikagaku Corporation | Agent for applying to mucosa and method for production thereof |
| JP2008255061A (ja) * | 2007-04-06 | 2008-10-23 | Shiseido Co Ltd | 可溶性架橋ヒアルロン酸含有眼用組成物 |
| WO2009025763A2 (en) * | 2007-08-16 | 2009-02-26 | Schepens Eye Research Institute | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| RU2015129822A (ru) * | 2008-05-15 | 2015-11-10 | Р-Тек Уено, Лтд. | Фармацевтическая композиция для лечения сухости глаз и/или повреждения конъюнктивы и роговицы |
| JP5595206B2 (ja) * | 2009-09-30 | 2014-09-24 | ロート製薬株式会社 | 眼科用液体組成物 |
| US8283463B2 (en) * | 2010-02-09 | 2012-10-09 | Bausch & Lomb Incorporated | Sterile hyaluronic acid solutions |
| LT2598526T (lt) * | 2010-07-29 | 2018-10-10 | Eleven Biotherapeutics, Inc. | Chimeriniai il-1 receptoriaus i tipo agonistai ir antagonistai |
| KR20170018462A (ko) * | 2010-09-10 | 2017-02-17 | 산텐 세이야꾸 가부시키가이샤 | Ｐ2ｙ2 수용체 작동약 및 히알루론산 또는 그 염을 조합한 것을 특징으로 하는 드라이 아이 치료제, 드라이 아이의 치료 방법, 및 그 용도 |
| KR20170100483A (ko) * | 2014-12-02 | 2017-09-04 | 리제너론 파마슈티칼스 인코포레이티드 | 건성안을 위한 동물 모델 및 이러한 동물의 이용 방법 |
| SG10201901426WA (en) * | 2015-03-06 | 2019-03-28 | Santen Pharmaceutical Co Ltd | Ophthalmic composition |
| US20170014339A1 (en) | 2015-07-17 | 2017-01-19 | i.com medical GmbH | Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute |
| HUE058672T2 (hu) | 2016-10-14 | 2022-09-28 | I Com Medical Gmbh | Eljárás a szemfelület homeosztázisának megállapítására, helyreállítására és megõrzésére |
| WO2019202017A1 (en) * | 2018-04-18 | 2019-10-24 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| US12268706B2 (en) * | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
-
2017
- 2017-10-02 HU HUE17817868A patent/HUE058672T2/hu unknown
- 2017-10-02 EP EP17817868.7A patent/EP3525799B1/en active Active
- 2017-10-02 JP JP2019541893A patent/JP2019532105A/ja active Pending
- 2017-10-02 WO PCT/IB2017/001364 patent/WO2018069763A1/en not_active Ceased
- 2017-10-02 KR KR1020197013278A patent/KR20190068575A/ko not_active Ceased
- 2017-10-02 PL PL17817868T patent/PL3525799T3/pl unknown
- 2017-10-02 EP EP21167346.2A patent/EP3871682A1/en active Pending
- 2017-10-02 ES ES17817868T patent/ES2909998T3/es active Active
- 2017-10-02 US US16/341,915 patent/US20190240251A1/en active Pending
-
2022
- 2022-07-29 JP JP2022122165A patent/JP2022153583A/ja active Pending
-
2024
- 2024-12-02 JP JP2024209810A patent/JP2025029084A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532105A5 (cg-RX-API-DMAC7.html) | ||
| US20230404961A1 (en) | Ophthalmic compositions and methods for treating eyes | |
| CN111991415B (zh) | 一种眼部护理组合物及其制备方法和用途 | |
| JP2009515921A (ja) | デクスパンテノール、カルシウムイオン、およびリン酸塩を含まない薬学的組成物、ならびにカルシウムキレート剤および眼科的に適合性の粘性調節剤の使用 | |
| US10279046B2 (en) | Eye drop composition for treating ocular inflammatory disease and preparation method therefor | |
| US20070141091A1 (en) | Biguanide ointment and method of treatment and prevention of infections | |
| US7820639B2 (en) | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same | |
| US9233123B1 (en) | Use of ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan | |
| US8551974B1 (en) | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same | |
| KR101723703B1 (ko) | 안구 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물 | |
| JP2008189677A (ja) | 洗浄剤 | |
| WO2021101883A1 (en) | Chitosan containing compositions and methods relating to same | |
| WO2020140365A1 (zh) | 一种含有黄原胶的保湿润滑组合物及其应用 | |
| CN106265720A (zh) | 一种复合人工泪液及其制备方法 | |
| JP2023038930A (ja) | 眼表面薬物滞留化剤およびこれを含む点眼剤、並びに、これらの剤を用いた眼表面薬物滞留方法および眼科疾患治療方法 | |
| CN102727874B (zh) | 重组水蛭素滴眼液及其制备方法 | |
| KR20220008720A (ko) | 카라기난을 포함하는 점안용 조성물 | |
| US20190151352A1 (en) | Ophthalmic composition comprising a synergistic combination of glycogen and hyaluronic acid or a salt thereof | |
| TR2025013194A1 (tr) | Hyaluroni̇k asi̇t, dekspantenol ve çay ağaci yaği özütü olan terpi̇nen-4-ol i̇çeren göz damlasi formülasyonu | |
| CN118526516A (zh) | 一种高渗透性的隐形眼镜护理液及其制备方法 | |
| US20250302868A1 (en) | Hypochlorous acid-based dry eye formulations | |
| JP2014513118A (ja) | 結膜弛緩症治療用の点眼薬 | |
| CN107412215A (zh) | 一种滴眼剂及其制备方法 | |
| HK1125027B (en) | Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator | |
| JP2004043516A (ja) | 眼科用剤 |